InflaRX raises US$55m in Series D roundGerman infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance … more ➔
Targovax reports 100% one-year survival in... Norwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients. more ➔
Sanofi invests €170m to expand flu jab f...Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year. more ➔
Researchers describe alternative psoriasis...British researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want … more ➔
Neurim tables Phase III data of insomnia d...German-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD). more ➔
Erytech Pharma set to raise US$100m in IPO...French cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials … more ➔
uniQures AMT-130 receives FDA Orphan Dru... As first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntingtons Disease. more ➔
Promethera Biosciences partners with Shibu... Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform. more ➔
Immatics raises $58m Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well … more ➔
NuCana raises US$114m in IPO of ADSsScotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair. more ➔
